12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333+RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

被引：42
|
作者：
Poordad, F. [1 ]
Lawitz, E. [2 ]
Kowdley, K. V. [3 ]
Everson, G. T. [4 ]
Freilich, B. [5 ]
Cohen, D. [6 ]
Siggelkow, S. [6 ]
Heckaman, M. [6 ]
Menon, R. [6 ]
Pilot-Matias, T. [6 ]
Podsadecki, T. [6 ]
Bernstein, B. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Alamo Med Res, San Antonio, TX USA
[3] Virginia Mason Med Ctr, Digest Dis Inst, Seattle, WA 98101 USA
[4] Univ Colorado Denver & Hosp, Aurora, CO USA
[5] Kansas City Gastroenterol & Hepatol, Kansas City, MO USA
[6] Abbott, Abbott Pk, IL USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61410-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1399
引用
收藏
页码：S549 / S550
页数：2
相关论文
共 34 条
  • [1] A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection
    Kowdley, Kris V.
    Lawitz, Eric
    Poordad, Fred
    Cohen, Daniel E.
    Nelson, David R.
    Zeuzem, Stefan
    Everson, Gregory T.
    Kwo, Paul Y.
    Foster, Graham R.
    Sulkowski, Mark S.
    Xie, Wangang
    Pilot-Matias, Tami
    Liossis, George
    Larsen, Lois M.
    Khatri, Amit
    Podsadecki, Thomas J.
    Bernstein, Barry
    HEPATOLOGY, 2012, 56 (06) : 1515 - 1516
  • [2] A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS
    Lawitz, E.
    Poordad, F.
    Kowdley, K. V.
    Jensen, D.
    Cohen, D. E.
    Siggelkow, S.
    Wikstrom, K.
    Larsen, L.
    Menon, R. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S7 - S7
  • [3] Pearl-IV: a 12-Week Regimen of ABT-450/r/ABT-267 and ABT-333, With or Without Ribavirin Achieves Svr12 Rates ≥90% in Treatment-Naive Adults Infected With Hepatitis C Virus Genotype 1A
    Bernstein, David
    Lalezari, Jacob
    Luo, Yan
    Box, Terry D.
    Younes, Ziad H.
    Green, Sinikka
    Bhandari, Bai R.
    Sepe, Thomas
    Cooper, Curtis
    Tam, Edward
    Tsai, Naoky
    Hassanein, Tarek
    Xie, Wangang
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S977 - S978
  • [4] SVR12 of 99% achieved with a ribavirin-free regimen ABT-450/R/ombitasvir and dasabuvir in HCV genotype 1b-infected patients
    Maieron, A.
    Puoti, M.
    Enejosa, J. V.
    Andreone, P.
    Ari, Z. B.
    Norkrans, G.
    Romero-Gomez, M.
    Xie, W.
    Cohen, D. E.
    Podsadecki, T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 156 - 156
  • [5] SVR12 of 99% Achieved With a Ribavirin-Free Regimen of ABT-450/r/Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
    Maieron, Andreas
    Puoti, Massimo
    Enejosa, Jeffrey
    Ben-Ari, Ziv
    Norkrans, Gunnar
    Romero-Gomez, Manuel
    Xie, Wangang
    Cohen, Daniel
    Podsadecki, Thomas
    Andreone, Pietro
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S131 - S131
  • [6] ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS
    Lawitz, E.
    Poordad, F.
    DeJesus, E.
    Kowdley, K.
    Gaultier, I.
    Cohen, D.
    Xie, W.
    Larsen, L.
    Pilot-Matias, T.
    Menon, R. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S470 - S470
  • [7] SAPPHIRE I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 631 Treatment-Naive Adults With Hepatitis C Virus Genotype 1
    Kowdley, Kris V.
    Feld, Jordan J.
    Coakley, Eoin
    Sigal, Samuel
    Nelson, David R.
    Crawford, Darrell
    Weiland, Ola
    Aguilar, Humberto
    Xiong, Junyuan
    DaSilva-Tillmann, Barbara
    Larsen, Lois
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S912 - S913
  • [8] SAPPHIRE I: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN 631 TREATMENT-NAIVE ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
    Feld, J. J.
    Kowdley, K. V.
    Coakley, E.
    Sigal, S.
    Nelson, D.
    Crawford, D.
    Weiland, O.
    Aguilar, H.
    Xiong, J.
    DaSilva-Tillmann, B.
    Larsen, L.
    Podsadecki, T.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S25 - S25
  • [9] Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-naive Patients and Prior Null Responders
    Lawitz, Eric
    Hezode, Christophe
    Varunok, Peter
    Thuluvath, Paul J.
    Baykal, Tolga
    Kapoor, Mudra
    Lovell, Sandra S.
    Wang, Tianli
    Pilot-Matias, Tami
    Vilchez, Regis A.
    Bernstein, Barry
    HEPATOLOGY, 2013, 58 : 244A - 244A
  • [10] PEARL-III: 12 WEEKS OF ABT-450/R/267+ABT-333 ACHIEVED SVR IN >99% OF 419 TREATMENT-NAIVE HCV GENOTYPE 1B-INFECTED ADULTS WITH OR WITHOUT RIBAVIRIN
    Ferenci, P.
    Nyberg, A.
    Enayati, P.
    Bernstein, D.
    Baruch, Y.
    Caruntu, F. A.
    Chulanov, V.
    Janczewska, E.
    Younes, Z.
    Marinho, R. T.
    Rizzardini, G.
    Gervain, J.
    Planas, R.
    Moreno, C.
    Xie, W.
    Cohen, D.
    King, M.
    Podsadecki, T.
    Reddy, K. R.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S527 - S527
1234